Paper41335261
Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application.
Zhang Y and 7 others. Mol Biol Rep, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application. Papers, record 41335261. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41335261
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Tumor Microenvironment | Major topic |
| Immunotherapy | Major topic |
| Humans | |
| Killer Cells, Natural | |
| T-Lymphocytes, Regulatory | |
| Dendritic Cells | |
| Antibodies, Bispecific | |
| Myeloid-Derived Suppressor Cells | |
| Animals |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| No. 2022JJ40003 | Natural Science Foundation for Youth of Hunan Province | PubMed | ||
| No.2024JJ7018 | Natural Science Foundation of Hunan Province | PubMed | ||
| No.2023YD30 | Changde Science and Technology Board | PubMed |
Source PubMed
References97
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16150935 | Dysfunctional T regulatory cells in multiple myeloma. | Blood | 2006 | https://conductscience.org/library/papers/16150935 | PubMed |
| 2 | 38424196 | Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. | Nat Rev Clin Oncol | 2024 | https://conductscience.org/library/papers/38424196 | PubMed |
| 3 | 38783333 | BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/38783333 | PubMed |
| 4 | 29359507 | Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. | Immunol Cell Biol | 2018 | https://conductscience.org/library/papers/29359507 | PubMed |
| 5 | 34459681 | Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. | Ann Med | 2021 | https://conductscience.org/library/papers/34459681 | PubMed |
| 6 | 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet | 2021 | https://conductscience.org/library/papers/34175021 | PubMed |
| 7 | 39820043 | A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast. | Sci Rep | 2025 | https://conductscience.org/library/papers/39820043 | PubMed |
| 8 | 34072068 | CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34072068 | PubMed |
| 9 | 22804669 | Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. | Br J Haematol | 2012 | https://conductscience.org/library/papers/22804669 | PubMed |
| 10 | 38466644 | Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma. | Clin Cancer Res | 2024 | https://conductscience.org/library/papers/38466644 | PubMed |
| 11 | 39855377 | Regulation of PD-L1 glycosylation and advances in cancer immunotherapy. | Cancer Lett | 2025 | https://conductscience.org/library/papers/39855377 | PubMed |
| 12 | 39261906 | Updates on CAR T cell therapy in multiple myeloma. | Biomark Res | 2024 | https://conductscience.org/library/papers/39261906 | PubMed |
| 13 | 35661166 | Teclistamab in Relapsed or Refractory Multiple Myeloma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35661166 | PubMed |
| 14 | 27269947 | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. | J Clin Oncol | 2016 | https://conductscience.org/library/papers/27269947 | PubMed |
| 15 | 23321256 | Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. | Blood | 2013 | https://conductscience.org/library/papers/23321256 | PubMed |
| 16 | 37883186 | BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. | J Clin Invest | 2024 | https://conductscience.org/library/papers/37883186 | PubMed |
| 17 | 38242888 | Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. | Nat Commun | 2024 | https://conductscience.org/library/papers/38242888 | PubMed |
| 18 | 38052709 | Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study. | Clin Lymphoma Myeloma Leuk | 2024 | https://conductscience.org/library/papers/38052709 | PubMed |
| 19 | 36413710 | Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36413710 | PubMed |
| 20 | 37501530 | T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA. | Curr Opin Oncol | 2023 | https://conductscience.org/library/papers/37501530 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42142763 | Nanoparticle-Based delivery of proteasome inhibitors for glioblastoma Therapy: Strategies to overcome Blood-Brain barrier and therapeutic resistance. | Biochem Pharmacol | 2026 | https://conductscience.org/library/papers/42142763 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41335261
GET https://conductscience.org/api/papers/v1/41335261/references?page=2